Form 4: Hologic Director Sally Crawford Reports Stock Transactions

Director Sally Crawford reports acquisition and disposal of Hologic Inc. stock and stock options.

Summary

• On March 7, 2024, Sally Crawford, a director of Hologic Inc., acquired 1,572 shares of common stock through restricted stock units.
• On March 8, 2024, she exercised options to acquire 9,039 shares at a price of $26.74.
• Also on March 8, 2024, she sold 9,039 shares at a weighted average price of $76.403, with prices ranging from $76.40 to $76.43.
• Following these transactions, Crawford directly owns 132,927 shares of common stock.
• She also holds 4,536 non-qualified stock options with an exercise price of $76.32, which become exercisable on the date of the 2025 Annual Meeting of Stockholders.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The exercise of stock options and subsequent sale of shares could be seen as a positive sign, indicating confidence in the company's prospects, although it is also a way for the director to realize gains.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies like Hologic.
• Comparing Crawford's transactions to those of other directors in similar medical technology companies (e.g., Intuitive Surgical, Medtronic) would require analyzing their respective Form 4 filings.
• The size and frequency of these transactions are typical for directors holding significant equity in their companies.

Stakeholder Impact

• The transactions may influence investor perception of the company, although individual insider transactions are not always indicative of overall company health.
• Transparency in insider trading activity helps maintain investor confidence.

Next Steps

• The restricted stock units acquired on March 7, 2024, will vest on the date of the 2025 Annual Meeting of Stockholders.
• The non-qualified stock options become exercisable on the date of the 2025 Annual Meeting of Stockholders.

Key Dates